ViraCyte Awarded $3.75M from NIH and FDA to Advance T Cell Immunotherapies – Pharmaceutical Processing
Pharmaceutical Processing |
ViraCyte Awarded $3.75M from NIH and FDA to Advance T Cell Immunotherapies
Pharmaceutical Processing ViraCyte, LLC, a clinical stage biopharmaceutical company developing cellular immunotherapies for severe infections, this week announced that it has been awarded $3.75 million from National Institutes of Health (NIH) and the Food and Drug … |
